309 related articles for article (PubMed ID: 20449688)
1. PACAP/VIP and receptor characterization in micturition pathways in mice with overexpression of NGF in urothelium.
Girard BM; Malley SE; Braas KM; May V; Vizzard MA
J Mol Neurosci; 2010 Nov; 42(3):378-89. PubMed ID: 20449688
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP-induced cystitis on PACAP/VIP and receptor expression in micturition pathways and bladder function in mice with overexpression of NGF in urothelium.
Girard BM; Tompkins JD; Parsons RL; May V; Vizzard MA
J Mol Neurosci; 2012 Nov; 48(3):730-43. PubMed ID: 22700375
[TBL] [Abstract][Full Text] [Related]
3. PACAP-mediated ATP release from rat urothelium and regulation of PACAP/VIP and receptor mRNA in micturition pathways after cyclophosphamide (CYP)-induced cystitis.
Girard BM; Wolf-Johnston A; Braas KM; Birder LA; May V; Vizzard MA
J Mol Neurosci; 2008 Nov; 36(1-3):310-20. PubMed ID: 18563302
[TBL] [Abstract][Full Text] [Related]
4. Intravesical PAC1 Receptor Antagonist, PACAP(6-38), Reduces Urinary Bladder Frequency and Pelvic Sensitivity in NGF-OE Mice.
Girard BM; Malley SE; Mathews MM; May V; Vizzard MA
J Mol Neurosci; 2016 Jun; 59(2):290-9. PubMed ID: 27146136
[TBL] [Abstract][Full Text] [Related]
5. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
6. Early Alterations of PACAP and VIP Expression in the Female Rat Brain Following Spinal Cord Injury.
Broome ST; Mandwie M; Gorrie CA; Musumeci G; Marzagalli R; Castorina A
J Mol Neurosci; 2023 Oct; 73(9-10):724-737. PubMed ID: 37646964
[TBL] [Abstract][Full Text] [Related]
7. VIP and PACAP effects on mouse major pelvic ganglia neurons.
Tompkins JD; Girard BM; Vizzard MA; Parsons RL
J Mol Neurosci; 2010 Nov; 42(3):390-6. PubMed ID: 20428965
[TBL] [Abstract][Full Text] [Related]
8. Neurotrophin/receptor expression in urinary bladder of mice with overexpression of NGF in urothelium.
Girard BM; Malley SE; Vizzard MA
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F345-55. PubMed ID: 21048026
[TBL] [Abstract][Full Text] [Related]
9. The role of vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide in the neural pathways controlling the lower urinary tract.
Yoshiyama M; de Groat WC
J Mol Neurosci; 2008 Nov; 36(1-3):227-40. PubMed ID: 18677446
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Moody TW; Nuche-Berenguer B; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):38-47. PubMed ID: 26702849
[TBL] [Abstract][Full Text] [Related]
11. Intrabladder PAC1 Receptor Antagonist, PACAP(6-38), Reduces Urinary Bladder Frequency and Pelvic Sensitivity in Mice Exposed to Repeated Variate Stress (RVS).
Girard BM; Campbell SE; Beca KI; Perkins M; Hsiang H; May V; Vizzard MA
J Mol Neurosci; 2021 Aug; 71(8):1575-1588. PubMed ID: 32613552
[TBL] [Abstract][Full Text] [Related]
12. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.
Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V
Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946
[TBL] [Abstract][Full Text] [Related]
13. Role for pituitary adenylate cyclase activating polypeptide in cystitis-induced plasticity of micturition reflexes.
Braas KM; May V; Zvara P; Nausch B; Kliment J; Dunleavy JD; Nelson MT; Vizzard MA
Am J Physiol Regul Integr Comp Physiol; 2006 Apr; 290(4):R951-62. PubMed ID: 16322346
[TBL] [Abstract][Full Text] [Related]
14. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
15. PACAP expression in explant cultured mouse major pelvic ganglia.
Girard BM; Galli JR; Young BA; Vizzard MA; Parsons RL
J Mol Neurosci; 2010 Nov; 42(3):370-7. PubMed ID: 20407844
[TBL] [Abstract][Full Text] [Related]
16. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
17. PACAP and its receptors in cranial arteries and mast cells.
Jansen-Olesen I; Hougaard Pedersen S
J Headache Pain; 2018 Feb; 19(1):16. PubMed ID: 29460121
[TBL] [Abstract][Full Text] [Related]
18. A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.
Ramos-Álvarez I; Mantey SA; Nakamura T; Nuche-Berenguer B; Moreno P; Moody TW; Maderdrut JL; Coy DH; Jensen RT
Peptides; 2015 Apr; 66():26-42. PubMed ID: 25698233
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
20. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
